Drug
Igsc 20
Igsc 20: highest development phase Post-Market, developed by Grifols. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Grifols
Trials
| Drug | Phase | Indication |
|---|---|---|
| IGSC 20% NCT04566692 | Post-Market | Primary Immunodeficiency |
Latest
No recent events.
Follow Igsc 20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.